Jefferies increased its price target for Regeneron to $930, citing an expanded partnership with Sanofi to develop four new long-acting antibodies targeting inflammatory pathways. Sanofi will pay Regeneron $1 billion upfront, with potential milestone payments up to $7 billion, aiming to secure future revenue beyond Dupixent's exclusivity. This deal strengthens their pipeline with drugs expected to launch from 2030, supporting long-term growth amid competitive pressures. Regeneron's stock currently trades about 25.5% below the new target, reflecting significant upside potential.
Following Jefferies' price target increase for Regeneron, the stock trades at USD 740.17 on Pluang as of Oct 02, 2026 02:31 WIB, down 2.39% for the day and below its 52-week high of USD 852.03. Sanofi shares are priced at USD 40.87, down 0.89%, near their 52-week low of USD 40.74. On Pluang, Regeneron sees a buying interest with 71% of orders as of the same time.
Regeneron and Sanofi have expanded their antibody collaboration to include new candidates targeting IL-4 and IL-13 pathways for next-generation inflammation and immunology treatments. The deal provides Regeneron with $1 billion upfront and up to $7 b...
Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...
Biohaven announced that Phase 1 data for BHV-1530, a novel FGFR3-targeting antibody-drug conjugate for advanced cancers, will be presented at the ENA 2026 symposium. BHV-1530 has demonstrated early clinical activity with a favorable safety profile, a...
